Robert Zeiser
Robert Zeiser
Professor of Medicine, University of Freiburg
Verified email at - Homepage
Cited by
Cited by
Origin, fate and dynamics of macrophages at central nervous system interfaces
T Goldmann, P Wieghofer, MJC Jordão, F Prutek, N Hagemeyer, ...
Nature immunology 17 (7), 797-805, 2016
Acute graft-versus-host disease—biologic process, prevention, and therapy
R Zeiser, BR Blazar
New England Journal of Medicine 377 (22), 2167-2179, 2017
Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
R Zeiser, VH Nguyen, A Beilhack, M Buess, S Schulz, J Baker, CH Contag, ...
Blood 108 (1), 390-399, 2006
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ...
Leukemia 29 (10), 2062-2068, 2015
Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R
K Wilhelm, J Ganesan, T Müller, C Dürr, M Grimm, A Beilhack, CD Krempl, ...
Nature medicine 16 (12), 1434-1438, 2010
Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment
G Mikhaylov, U Mikac, AA Magaeva, VI Itin, EP Naiden, I Psakhye, ...
Nature nanotechnology 6 (9), 594-602, 2011
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
R Zeiser, DB Leveson-Gower, EA Zambricki, N Kambham, A Beilhack, ...
Blood, The Journal of the American Society of Hematology 111 (1), 453-462, 2008
Pathophysiology of chronic graft-versus-host disease and therapeutic targets
R Zeiser, BR Blazar
New England Journal of Medicine 377 (26), 2565-2579, 2017
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
S Spoerl, NR Mathew, M Bscheider, A Schmitt-Graeff, S Chen, T Mueller, ...
Blood, The Journal of the American Society of Hematology 123 (24), 3832-3842, 2014
CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation
K Rakhra, P Bachireddy, T Zabuawala, R Zeiser, L Xu, A Kopelman, ...
Cancer cell 18 (5), 485-498, 2010
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease
R Zeiser, N von Bubnoff, J Butler, M Mohty, D Niederwieser, R Or, J Szer, ...
New England Journal of Medicine 382 (19), 1800-1810, 2020
Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma
T Flecken, N Schmidt, S Hild, E Gostick, O Drognitz, R Zeiser, ...
Hepatology 59 (4), 1415-1426, 2014
Continuous T cell receptor signals maintain a functional regulatory T cell pool
JC Vahl, C Drees, K Heger, S Heink, JC Fischer, J Nedjic, N Ohkura, ...
Immunity 41 (5), 722-736, 2014
In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation
VH Nguyen, R Zeiser, DL DaSilva, DS Chang, A Beilhack, CH Contag, ...
Blood 109 (6), 2649-2656, 2007
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage
L Schwab, L Goroncy, S Palaniyandi, S Gautam, A Triantafyllopoulou, ...
Nature medicine 20 (6), 648-654, 2014
Lack of the purinergic receptor P2X7 results in resistance to contact hypersensitivity
FC Weber, PR Esser, T Müller, J Ganesan, P Pellegatti, MM Simon, ...
Journal of Experimental Medicine 207 (12), 2609-2619, 2010
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity
R Nishimura, J Baker, A Beilhack, R Zeiser, JA Olson, EI Sega, M Karimi, ...
Blood, The Journal of the American Society of Hematology 112 (6), 2563-2574, 2008
The Nlrp3 inflammasome regulates acute graft-versus-host disease
D Jankovic, J Ganesan, M Bscheider, N Stickel, FC Weber, G Guarda, ...
Journal of Experimental Medicine 210 (10), 1899-1910, 2013
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European …
O Penack, M Marchetti, T Ruutu, M Aljurf, A Bacigalupo, F Bonifazi, ...
The Lancet Haematology 7 (2), e157-e167, 2020
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ...
Nature medicine 24 (3), 282-291, 2018
The system can't perform the operation now. Try again later.
Articles 1–20